Four area hospitals link up to ‘my health care' app
Having your own medical information available on your phone could make life easier.
Barrie's Royal Victoria Regional Health Centre, Collingwood General and Marine Hospital, Midland's Georgian Bay General Hospital and Orangeville's Headwaters Health Care Centre have joined forces to simplify healthcare for their collective or singular patients.
As of July 30, health records will be available on iPhones and iPads as part of the Health app, which also shows activity, heart rate, nutrition and other health data consolidated from iPhone, iPad, Apple Watch and HealthKit-enabled third-party apps.
This brings together hospitals, clinics and the existing Apple Health app to make it easy for patients to see their available medical data from multiple providers whenever they choose.
'We're continually enhancing our digital tools to make it easier for patients to access and understand their health information,' said Dave Brewin, regional chief information officer for the four partner sites.
'Health Records offers a convenient and secure way for patients to stay connected to their care. It's another important step in supporting patients to be more engaged, informed and empowered.'
The four hospitals, which share the my health care patient portal, have integrated with Apple Health Records to provide patients with simple, on-demand access to their health data — all in one place.
Health data from all four hospitals — and other providers using Apple Health — is available in one convenient, consolidated view.
Health Records creates a direct connection between medical institutions and a patient's iPhone or iPad, allowing them to see a central view of their allergies, clinical notes, conditions, immunizations, lab results, medications, procedures and vitals. It also notifies patients when their data is updated.
Health Records is designed to protect patients' privacy through a direct, encrypted connection between the user's iPhone or iPad and the medical institution.
Downloaded health records' data is stored on your device and encrypted with the user's iPhone or iPad passcode, Touch ID or Face ID.
Patients can now access Health Records from within the Health app and can download their health records by selecting any of the four hospital names and authenticating with their patient portal username and password.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
33 minutes ago
- Globe and Mail
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
NEW YORK, Aug. 05, 2025 (GLOBE NEWSWIRE) -- via InvestorWire — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the full publication, 'Late-Stage Pipeline Wins Boost Investor Confidence in High-Growth Therapeutic Areas,' please visit: As America's population ages, chronic and rare diseases are emerging as a pressing healthcare challenge — one that disproportionately affects older adults. With more than 30 million Americans living with a rare disease, the need for accurate diagnoses and effective treatments is growing urgent. Many of these conditions remain without FDA-approved therapies, and symptoms in seniors are often misattributed to typical aging, leading to years-long diagnostic delays. Recognizing this crisis, the Trump administration's 'Make America Healthy Again' initiatives have emphasized improving access to treatments and accelerating medical innovation. Advancing this mission, Soligenix Inc. (NASDAQ: SNGX) is making strides with its HyBryte(TM) platform, a novel therapy aimed at treating cutaneous T-cell lymphoma (CTCL), a rare skin cancer that primarily affects older adults. With successful U.S.-based manufacturing of HyBryte's active ingredient now in place, Soligenix exemplifies the kind of domestic innovation poised to make a meaningful impact on this underserved patient population. About Soligenix Inc. Soligenix is a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need. Its Specialized BioTherapeutics business segment is developing and moving toward potential commercialization of HyBryte(TM) ('SGX301' or synthetic hypericin) as a novel photodynamic therapy utilizing safe visible light for the treatment of cutaneous T-cell lymphoma ('CTCL'). With successful completion of the second Phase 3 study, regulatory approvals will be sought to support potential commercialization worldwide. Development programs in this business segment also include expansion of synthetic hypericin ('SGX302') into psoriasis, the company's first-in-class innate defense regulator ('IDR') technology, dusquetide ('SGX942') for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer, and ('SGX945') in Behçet's disease. The company's Public Health Solutions business segment includes development programs for RiVax(R), its ricin toxin vaccine candidate, as well as its vaccine programs targeting filoviruses (such as Marburg and Ebola) and CiVax(TM), the company's vaccine candidate for the prevention of COVID-19 (caused by SARS-CoV-2). The development of Soligenix's vaccine programs incorporates the use of its proprietary heat stabilization platform technology, known as ThermoVax(R). To date, this business segment has been supported with government grants and contract funding from the National Institute of Allergy and Infectious Diseases ('NIAID'), the Defense Threat Reduction Agency ('DTRA') and the Biomedical Advanced Research and Development Authority ('BARDA'). For further information, visit the company's website at . About NetworkNewsWire NetworkNewsWire ('NNW') is a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. It is one of 60+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, NNW brings its clients unparalleled recognition and brand awareness. NNW is where breaking news, insightful content and actionable information converge. For more information, please visit
National Post
2 hours ago
- National Post
Canopy Growth Expands Global Medical Portfolio with Launch of 7ACRES in Australia
Article content SMITHS FALLS, Ontario — Canopy Growth Corporation ('Canopy Growth' or the 'Company') (TSX: WEED) (Nasdaq: CGC), a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives, has introduced its Canadian-grown 7ACRES brand in Australia, expanding the Company's medical cannabis offering with two high-THC sativa strains: Ultra Jack and Jack Frost. Article content Ultra Jack, a cross of Ultra Sour and Jack Haze, is one of 7ACRES' top performing flower strains in the Canadian medical and adult-use cannabis markets. Jack Frost, a cross of White Widow and Cold Creek Kush, adds further genetic depth to the lineup. Both strains are initially available in 10g flower formats. Article content 'Adding 7ACRES to our Australian portfolio helps ensure patients and prescribers have access to a diverse range of high-quality flower options,' said Andrew Bevan, SVP, Global Medical. 'With recent improvements to our global supply chain, we're positioned to deliver these strains with consistent quality and reliable access to patients in Australia.' Article content 'Global medical is one of Canopy Growth's largest commercial opportunities,' said Luc Mongeau, Chief Executive Officer. 'Our ability to scale high-quality production in Canada and reliably supply international markets remains a key strength as we expand our global medical platform.' Article content The introduction of 7ACRES complements Canopy Growth's existing presence in Australia, which includes Tweed flower products as well as Spectrum Therapeutics oils available in Red, Yellow, White, and Blue formulations. Together, this expanded medical portfolio reflects Canopy Growth's focus on building a scalable medical platform across international markets. Article content About Canopy Growth Article content Canopy Growth is a world-leading cannabis company dedicated to unleashing the power of cannabis to improve lives. Article content Through an unwavering commitment to consumers, Canopy Growth delivers innovative products from owned and licensed brands including Tweed, 7ACRES, DOJA, Deep Space, and Claybourne, as well as category defining vaporization devices by Storz & Bickel. In addition, Canopy Growth serves medical cannabis patients globally with principal operations in Canada, Europe and Australia. Article content Canopy Growth has also established a comprehensive ecosystem to realize the opportunities presented by the U.S. THC market through an unconsolidated, non-controlling interest in Canopy USA, LLC ('Canopy USA'). Canopy USA's portfolio includes ownership of Acreage Holdings, Inc., a vertically integrated multi‑state cannabis operator with operations throughout the U.S. Northeast and Midwest, as well as ownership of Wana Wellness, LLC, The Cima Group, LLC, and Mountain High Products, LLC, a leading North American edibles brand, and majority ownership of Lemurian, Inc., a California-based producer of high-quality cannabis extracts and clean vape technology. Article content At Canopy Growth, we're shaping a future where cannabis is embraced for its potential to enhance well-being and improve lives. With high-quality products, a commitment to responsible use, and a focus on enhancing the communities where we live and work, we're paving the way for a better understanding of all that cannabis can offer. Article content Article content Article content Article content Contacts Article content
Globe and Mail
2 hours ago
- Globe and Mail
3 Healthcare Stocks Paying the Highest Dividends of 2025
Key Points SIGA Technologies has a sky-high dividend yield that comes with a catch. Pfizer's dividend remains strong despite a looming patent cliff. Spok Holdings offers an attractive dividend and outstanding growth. 10 stocks we like better than Pfizer › The healthcare sector has long been a favorite for income investors -- and for good reason. Many healthcare stocks offer attractive dividend yields. Some stocks stand out more than others, though. Here are the three healthcare stocks paying the highest dividends in 2025. 1. SIGA Technologies SIGA Technologies (NASDAQ: SIGA) focuses primarily on developing drugs for treating orthopoxviruses. Its flagship product is TPOXX, an antiviral medication that's approved in the U.S. and Canada for treating smallpox and in Europe, Japan, and the U.K. for treating smallpox, mpox, cowpox, and vaccinia complications. The company's dividend yield is a lofty 9.29%. However, there's something investors should know about SIGA's dividend. The drugmaker doesn't pay a regular dividend but, instead, has declared special cash dividends for four consecutive years. Special cash dividends usually aren't viewed as favorably by income investors as established programs that pay dividends on a monthly or quarterly basis. The risk that a company will decide against paying a special cash dividend in the future is probably higher than the risk that a company will suspend a regular dividend. SIGA's ability to pay dividends in the future depends largely on how seriously governments perceive the threat posed by smallpox, mpox, and other orthopoxviruses. For now, the threat level is high. That probably bodes well for the company declaring a special cash dividend in 2026, but it's difficult to predict what will happen with SIGA's dividend beyond then. 2. Pfizer Pfizer (NYSE: PFE) is the most well-known of the high-paying healthcare dividend stocks on this list. The company was founded in 1849. Today, it's one of the biggest drugmakers on the planet, with a market cap of over $130 billion and a lineup that includes multiple blockbuster drugs. Income investors have a lot to like about Pfizer. Its forward dividend yield stands at 7.32%. The company has paid a dividend for 346 consecutive quarters and has increased its dividend for 16 consecutive years. Its management team remains committed to sustaining and growing the dividend. Pfizer faces some challenges that could limit how much it's able to increase the dividend over the next few years, though. By the end of 2028, the company will lose patent protection for kidney cancer drug Inlyta, autoimmune disease drug Xeljanz, blood thinner Eliquis, breast cancer drug Ibrance, prostate cancer drug Xtandi, rare-disease franchise Vyndaqel/Vyndamx, and Mektovi, which treats melanoma and non-small cell lung cancer. While this patent cliff admittedly looks daunting, Pfizer's dividend shouldn't be in danger. The drugmaker has several rising stars, including migraine therapy Nurtec ODT and cancer drugs Padcev, Lorbrena, and Elrexfio. Pfizer's pipeline is also loaded with promising candidates, including 30 late-stage programs. 3. Spok Holdings Spok Holdings (NASDAQ: SPOK) specializes in healthcare communication and collaboration solutions. The company's flagship product, Spok Care Connect, is a unified communication platform that provides closed-loop communication, secure messaging, and collaboration capabilities to clinical teams. While Spok mainly focuses on hospitals, it also sells products to large government agencies, public-safety institutions, academic institutions, and other commercial customers. There's good news and bad news with Spok's dividend. First, the bad news: Don't expect dividend increases. Spok hasn't increased its dividend since 2022. The good news, though, is that the dividend is attractive, with a forward yield of 6.75%. Want more good news? Spok's business is booming. The company's earnings jumped 33% year over year in the second quarter of 2025. Its software operations bookings were 34% higher than the prior-year period. Unsurprisingly, Spok's stock has also performed well and is handily beating the market so far this year. Should you invest $1,000 in Pfizer right now? Before you buy stock in Pfizer, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Pfizer wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $624,823!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,064,820!* Now, it's worth noting Stock Advisor's total average return is 1,019% — a market-crushing outperformance compared to 178% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025
